IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
11 déc. 2023 09h00 HE
|
IN8bio, Inc
Initial closing of $14.4 million to support operational execution and extend cash runway into 2025 with potential for up to $32.5 million in additional capital at increasing valuations Proceeds to...
IN8bio Appoints Dr. Corinne Epperly to Board of Directors
07 déc. 2023 08h00 HE
|
IN8bio, Inc
Internationally recognized immuno-oncology and cell therapy executive with 20 years of experience in innovative immunotherapies for solid and hematological cancersBoard-Certified physician-scientist...
IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia
05 déc. 2023 08h00 HE
|
IN8bio, Inc
Event will follow the presentation of INB-100 data in patients with hematologic malignancies at the American Society of Hematology (ASH) 65th Annual Meeting & Exposition on the evening of December...
IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma
20 nov. 2023 07h00 HE
|
IN8bio, Inc
All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months Most patients exceeded the expected median PFS based on age and...
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting
10 nov. 2023 07h00 HE
|
IN8bio, Inc
Company will present “late-breaker” poster detailing updated clinical data from Phase 1 trial of INB-200 Company-sponsored Phase 2 trial of INB-400 to be showcased in Trials-in-Progress (TIPs) poster...
IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
09 nov. 2023 16h00 HE
|
IN8bio, Inc
Completed dose escalation in Phase 1 Trial of INB-100 with updated clinical data to be presented at the American Society of Hematology (ASH) Annual Meeting on December 11, 2023 (Abstract Number:...
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
06 nov. 2023 08h00 HE
|
IN8bio, Inc
Data demonstrate the ability of single and repeat doses of INB-200, DeltEx drug-resistant immunotherapy (DRI) gamma-delta T cell therapy, to induce T cell persistence and a sustained immune response.A...
IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
03 nov. 2023 12h00 HE
|
IN8bio, Inc
This data represents a step forward in developing next-generation ‘off-the-shelf’ iPSC derived gamma-delta T cells. Our proprietary expansion methods are serum and feeder-free and have the potential...
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
02 nov. 2023 09h17 HE
|
IN8bio, Inc
New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patients with hematologic malignancies; updated data on durability of responses and...
IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium
01 nov. 2023 08h00 HE
|
IN8bio, Inc
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced...